Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

chemed corp. - CHE

CHE

Close Chg Chg %
580.96 0.58 0.10%

Pre-Market

581.54

+0.58 (0.10%)

Volume: 110.66K

Last Updated:

Apr 17, 2025, 4:00 PM EDT

Trade Now

Company Overview: chemed corp. - CHE

CHE Key Data

Open

$579.13

 Day Range

576.36 - 585.12

52 Week Range

512.12 - 623.61

 Market Cap

$8.50B

Shares Outstanding

14.61M

 Public Float

14.34M

Beta

0.49

 Rev. Per Employee

N/A

P/E Ratio

29.23

 EPS

$20.12

Yield

32.68%

 Dividend

$0.50

EX-DIVIDEND DATE

Feb 24, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

138.85K

  

CHE Performance

1 Week
 
 -1.97%
 
1 Month
 
 -2.09%
 
3 Months
 
 4.86%
 
1 Year
 
 -3.12%
 
5 Years
 
 29.01%
 

CHE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About chemed corp. - CHE

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.

CHE At a Glance

Chemed Corp.
255 East 5th Street
Cincinnati, Ohio 45202-4726
Phone 1-513-762-6690 Revenue 2.43B
Industry Hospital/Nursing Management Net Income 302.00M
Sector Health Services 2024 Sales Growth 7.369%
Fiscal Year-end 12 / 2025 Employees 15,695
View SEC Filings

CHE Valuation

P/E Current 29.234
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 26.641
Price to Sales Ratio 3.309
Price to Book Ratio 6.892
Price to Cash Flow Ratio 19.271
Enterprise Value to EBITDA 18.367
Enterprise Value to Sales 3.294
Total Debt to Enterprise Value 0.018

CHE Efficiency

Revenue/Employee 154,908.378
Income Per Employee 19,241.733
Receivables Turnover 14.205
Total Asset Turnover 1.378

CHE Liquidity

Current Ratio 1.382
Quick Ratio 1.353
Cash Ratio 0.624

CHE Profitability

Gross Margin 32.547
Operating Margin 15.34
Pretax Margin 16.43
Net Margin 12.421
Return on Assets 17.119
Return on Equity 27.123
Return on Total Capital 23.971
Return on Invested Capital 24.895

CHE Capital Structure

Total Debt to Total Equity 12.587
Total Debt to Total Capital 11.18
Total Debt to Total Assets 7.969
Long-Term Debt to Equity 8.806
Long-Term Debt to Total Capital 7.821
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Chemed Corp. - CHE

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
2.14B 2.13B 2.26B 2.43B
Sales Growth
+2.87% -0.20% +6.06% +7.37%
Cost of Goods Sold (COGS) incl D&A
1.43B 1.43B 1.53B 1.64B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
59.05M 59.17M 60.87M 63.05M
Depreciation
49.01M 49.10M 50.80M 52.86M
Amortization of Intangibles
10.04M 10.07M 10.06M 10.19M
COGS Growth
-0.44% +0.04% +6.82% +7.44%
Gross Income
710.75M 705.91M 737.95M 791.30M
Gross Income Growth
+10.23% -0.68% +4.54% +7.23%
Gross Profit Margin
+33.22% +33.06% +32.59% +32.55%
2021 2022 2023 2024 5-year trend
SG&A Expense
368.58M 358.73M 395.12M 417.89M
Research & Development
- - - -
-
Other SG&A
368.58M 358.73M 395.12M 417.89M
SGA Growth
+11.62% -2.67% +10.15% +5.76%
Other Operating Expense
- - - 446.00K
-
Unusual Expense
(41.12M) 2.61M 2.05M 6.47M
EBIT after Unusual Expense
383.29M 344.57M 340.78M 366.49M
Non Operating Income/Expense
(31.10M) (10.31M) 12.70M 34.75M
Non-Operating Interest Income
377.00K 355.00K 6.27M 14.61M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.87M 4.58M 3.11M 1.78M
Interest Expense Growth
-20.68% +145.40% -32.20% -42.73%
Gross Interest Expense
1.87M 4.58M 3.11M 1.78M
Interest Capitalized
- - - -
-
Pretax Income
350.31M 329.68M 350.37M 399.46M
Pretax Income Growth
-11.53% -5.89% +6.28% +14.01%
Pretax Margin
+16.38% +15.44% +15.47% +16.43%
Income Tax
81.76M 80.06M 77.86M 97.47M
Income Tax - Current - Domestic
78.85M 64.72M 85.32M 101.10M
Income Tax - Current - Foreign
511.00K 505.00K 569.00K 501.00K
Income Tax - Deferred - Domestic
2.36M 14.82M (8.03M) (4.14M)
Income Tax - Deferred - Foreign
42.00K 6.00K 2.00K 2.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
268.55M 249.62M 272.51M 302.00M
Minority Interest Expense
- - - -
-
Net Income
268.55M 249.62M 272.51M 302.00M
Net Income Growth
-15.94% -7.05% +9.17% +10.82%
Net Margin Growth
+12.55% +11.69% +12.03% +12.42%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
268.55M 249.62M 272.51M 302.00M
Preferred Dividends
- - - -
-
Net Income Available to Common
268.55M 249.62M 272.51M 302.00M
EPS (Basic)
17.1368 16.7207 18.1069 20.1011
EPS (Basic) Growth
-14.41% -2.43% +8.29% +11.01%
Basic Shares Outstanding
15.67M 14.93M 15.05M 15.02M
EPS (Diluted)
16.8497 16.5325 17.9282 19.8867
EPS (Diluted) Growth
-13.51% -1.88% +8.44% +10.92%
Diluted Shares Outstanding
15.94M 15.10M 15.20M 15.19M
EBITDA
401.22M 406.36M 403.69M 436.01M
EBITDA Growth
+8.10% +1.28% -0.66% +8.01%
EBITDA Margin
+18.76% +19.03% +17.83% +17.93%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 663.667
Number of Ratings 4 Current Quarters Estimate 5.953
FY Report Date 06 / 2025 Current Year's Estimate 25.19
Last Quarter’s Earnings 5.56 Median PE on CY Estimate N/A
Year Ago Earnings 23.13 Next Fiscal Year Estimate 27.36
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 3 3
Mean Estimate 5.95 6.14 25.19 27.36
High Estimates 5.98 6.19 25.23 28.10
Low Estimate 5.93 6.12 25.17 26.91
Coefficient of Variance 0.42 0.66 0.14 2.36

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 1
HOLD 1 1 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Buy

Insider Actions for Chemed Corp. - CHE

Date Name Shares Transaction Value
Apr 2, 2025 Kevin J. McNamara president and CEO; Director 101,679 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $615.33 per share 62,566,139.07
Mar 12, 2025 Michael D. Witzeman VP & Chief Financial Officer 13,154 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $445.35 per share 5,858,133.90
Mar 12, 2025 Michael D. Witzeman VP & Chief Financial Officer 5,660 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $600.92 per share 3,401,207.20
Mar 12, 2025 Michael D. Witzeman VP & Chief Financial Officer 34,484 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 24, 2024 Spencer S. Lee executive vice president 24,542 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 24, 2024 Nicholas M. Westfall Executive Vice President 62,260 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 27, 2024 George J. Walsh Director 3,046 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $597.47 per share 1,819,893.62
Jun 14, 2024 Patrick P. Grace Director 3,270 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $540.98 per share 1,769,004.60
May 22, 2024 Thomas P. Rice Director 6,028 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $564.34 per share 3,401,841.52
May 22, 2024 Andrea R. Lindell Director 6,556 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $564.34 per share 3,699,813.04
May 22, 2024 Christopher J. Heaney Director 2,112 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $564.34 per share 1,191,886.08
May 22, 2024 John M. Mount Director 653 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $564.34 per share 368,514.02
May 22, 2024 Eileen P Mccarthy Director 578 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $564.34 per share 326,188.52
May 21, 2024 Ron DeLyons Director 1,389 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $564.34 per share 783,868.26

Chemed Corp. in the News